We are live on
!
Find out more
Puma Biotechnology
PBYI
PBYI
154 hedge funds and large institutions have $3.1B invested in Puma Biotechnology in 2017 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 48 increasing their positions, 48 reducing their positions, and 26 closing their positions.
New
Increased
Maintained
Reduced
Closed
200% more funds holding in top 10
Funds holding in top 10: 2 → 6 (+4)
120% more capital invested
Capital invested by funds: $1.41B → $3.1B (+$1.69B)
73% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 26
13% more funds holding
Funds holding: 136 → 154 (+18)
3% more call options, than puts
Call options by funds: $130M | Put options by funds: $125M
0% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 48
6.65% less ownership
Funds ownership: 102.74% → 96.09% (-6.7%)
Holders
154
Holders Change
+18
Holders Change %
+13.24%
% of All Funds
3.84%
Holding in Top 10
6
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+200%
% of All Funds
0.15%
New
45
Increased
48
Reduced
48
Closed
26
Calls
$130M
Puts
$125M
Net Calls
+$4.3M
Net Calls Change
+$6.02M
Top Buyers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$128M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$104M |
| 3 |
PA
Perceptive Advisors
New York
|
+$41M |
| 4 |
Millennium Management
New York
|
+$36.4M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$34.5M |
